These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2149834)

  • 1. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma.
    Ajani JA; Abbruzzese JL; Faintuch JS; Patt YZ; Boman BM; Jackson DE; Levin B; Krakoff IH
    Cancer Invest; 1990; 8(6):619-21. PubMed ID: 2149834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.
    Jolivet J; Landry L; Pinard MF; McCormack JJ; Tong WP; Eisenhauer E
    Cancer Chemother Pharmacol; 1987; 20(2):169-72. PubMed ID: 2959389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.
    Licht JD; Gonin R; Antman KH
    Cancer Chemother Pharmacol; 1991; 28(3):223-5. PubMed ID: 1830249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer.
    Maroun J
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):17-21. PubMed ID: 2835816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.
    Odujinrin O; Goldberg D; Doroshow J; Leong L; Margolin K; Grove W; Carr B; Akman S
    Med Pediatr Oncol; 1990; 18(1):49-52. PubMed ID: 2136764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
    Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
    Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
    Kris MG; D'Acquisto RW; Gralla RJ; Burke MT; Marks LD; Fanucchi MP; Heelan RT
    Am J Clin Oncol; 1989 Feb; 12(1):24-6. PubMed ID: 2536213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Ettinger DS; Donehower RC
    Cancer Chemother Pharmacol; 1989; 24(5):314-20. PubMed ID: 2758561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
    Gesme DH; Jett JR; Schreffler DD; Su JQ; Mailliard JA; Foley JF; Krook JE; Maksymiuk AW; Hatfield AK; Ebbert LP
    Cancer; 1993 May; 71(9):2723-6. PubMed ID: 8385564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer.
    Leiby JM
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):27-31. PubMed ID: 2966983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimetrexate as a single agent in patients with advanced head and neck cancer.
    Robert F
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):22-6. PubMed ID: 2966982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer.
    Mattson K; Maasilta P; Tammilehto L; Holsti LR; Grove W
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):32-7. PubMed ID: 2835817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
    Matin K; Jacobs SA; Richards T; Wong MK; Earle M; Evans T; Troetschel M; Ferri W; Friedland D; Pinkerton R; Volkin R; Wieand S; Ramanathan RK
    Am J Clin Oncol; 2005 Oct; 28(5):439-44. PubMed ID: 16199980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Dole GB; Rowinsky EK; Ettinger DS; Graham ML; McGuire WP; Donehower RC
    J Natl Cancer Inst; 1989 Jan; 81(2):124-30. PubMed ID: 2909752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
    Szelényi H; Hohenberger P; Lochs H; Haboubi N; Berdel WE; Thiel E; Kreuser ED
    Oncology; 2000 May; 58(4):273-9. PubMed ID: 10838491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
    Machiavelli MR; Salum G; Pérez JE; Ortiz EH; Romero AO; Bologna F; Vallejo CT; Lacava JA; Dominguez ME; Leone BA
    Am J Clin Oncol; 2004 Apr; 27(2):149-54. PubMed ID: 15057154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
    Blanke CD; Kasimis B; Schein P; Capizzi R; Kurman M
    J Clin Oncol; 1997 Mar; 15(3):915-20. PubMed ID: 9060528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of trimetrexate in recurrent anaplastic glioma. National Cancer Institute of Canada Clinical Trials Group Study.
    Cairncross JG; Eisenhauer EA; Macdonald DR; Rathbone MP; Moore MJ; Sawka CA; MacCormick RE; Kerr IG
    Can J Neurol Sci; 1990 Feb; 17(1):21-3. PubMed ID: 2138053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
    Conti JA; Kemeny N; Seiter K; Goker E; Tong W; André M; Ragusa K; Bertino JR
    J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.